Conference Proceedings

TheraP: A randomized phase II trial of [Lu-177]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer

Michael Hofman, Louise Emmett, John A Violet, Nicola Jane Lawrence, Scott Williams, Martin R Stockler, Roslyn J Francis, Amir Iravani, Alison Yan Zhang, Andrew James Martin, Arun Azad, Sonia Yip, Ailsa Langford, Margaret Mary McJannett, Ian D Davis

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2019

Abstract

TPS332 Background: Lutetium-177 [177Lu]-PSMA-617 is a novel radiolabelled small molecule that binds with high affinity to prostate-specific membrane antigen (PSMA), which is commonly overexpressed in prostate cancer. This treatment has demonstrated promising activity and tolerability in men progressing after multiple lines of chemotherapy and endocrine therapy. This trial will determine the activity and safety of 177Lu-PSMA-617 compared to cabazitaxel chemotherapy in men with progressive metastatic castrate resistant prostate cancer. Methods: TheraP is an open-label, randomised, two-arm, multi-centre, phase 2 trial comparing the activity and safety of experimental treatment with [177Lu]-PSM..

View full abstract